These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22150310)

  • 1. C/EBPα dysregulation in AML and ALL.
    Paz-Priel I; Friedman A
    Crit Rev Oncog; 2011; 16(1-2):93-102. PubMed ID: 22150310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.
    Pabst T; Mueller BU; Harakawa N; Schoch C; Haferlach T; Behre G; Hiddemann W; Zhang DE; Tenen DG
    Nat Med; 2001 Apr; 7(4):444-51. PubMed ID: 11283671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CCAAT/enhancer binding protein alpha (C/EBPalpha) and C/EBPalpha myeloid oncoproteins induce bcl-2 via interaction of their basic regions with nuclear factor-kappaB p50.
    Paz-Priel I; Cai DH; Wang D; Kowalski J; Blackford A; Liu H; Heckman CA; Gombart AF; Koeffler HP; Boxer LM; Friedman AD
    Mol Cancer Res; 2005 Oct; 3(10):585-96. PubMed ID: 16254192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the C/EBPα signaling pathway in acute myeloid leukemia (Review).
    Song G; Wang L; Bi K; Jiang G
    Oncol Rep; 2015 May; 33(5):2099-106. PubMed ID: 25760953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.
    Gombart AF; Hofmann WK; Kawano S; Takeuchi S; Krug U; Kwok SH; Larsen RJ; Asou H; Miller CW; Hoelzer D; Koeffler HP
    Blood; 2002 Feb; 99(4):1332-40. PubMed ID: 11830484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A C-terminal mutant of CCAAT-enhancer-binding protein α (C/EBPα-Cm) downregulates Csf1r, a potent accelerator in the progression of acute myeloid leukemia with C/EBPα-Cm.
    Togami K; Kitaura J; Uchida T; Inoue D; Nishimura K; Kawabata KC; Nagase R; Horikawa S; Izawa K; Fukuyama T; Nakahara F; Oki T; Harada Y; Harada H; Aburatani H; Kitamura T
    Exp Hematol; 2015 Apr; 43(4):300-8.e1. PubMed ID: 25534203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C/EBPα in normal and malignant myelopoiesis.
    Friedman AD
    Int J Hematol; 2015 Apr; 101(4):330-41. PubMed ID: 25753223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
    Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
    J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA).
    Preudhomme C; Sagot C; Boissel N; Cayuela JM; Tigaud I; de Botton S; Thomas X; Raffoux E; Lamandin C; Castaigne S; Fenaux P; Dombret H;
    Blood; 2002 Oct; 100(8):2717-23. PubMed ID: 12351377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex.
    Schmidt L; Heyes E; Scheiblecker L; Eder T; Volpe G; Frampton J; Nerlov C; Valent P; Grembecka J; Grebien F
    Leukemia; 2019 Jul; 33(7):1608-1619. PubMed ID: 30679799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain-of-Function Effects of N-Terminal CEBPA Mutations in Acute Myeloid Leukemia.
    Schmidt L; Heyes E; Grebien F
    Bioessays; 2020 Feb; 42(2):e1900178. PubMed ID: 31867767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infrequent hypermethylation of CEBPA promotor in acute myeloid leukaemia.
    Chim CS; Wong AS; Kwong YL
    Br J Haematol; 2002 Dec; 119(4):988-90. PubMed ID: 12472578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two types of C/EBPα mutations play distinct but collaborative roles in leukemogenesis: lessons from clinical data and BMT models.
    Kato N; Kitaura J; Doki N; Komeno Y; Watanabe-Okochi N; Togami K; Nakahara F; Oki T; Enomoto Y; Fukuchi Y; Nakajima H; Harada Y; Harada H; Kitamura T
    Blood; 2011 Jan; 117(1):221-33. PubMed ID: 20884804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia.
    Hollink IH; van den Heuvel-Eibrink MM; Arentsen-Peters ST; Zimmermann M; Peeters JK; Valk PJ; Balgobind BV; Sonneveld E; Kaspers GJ; de Bont ES; Trka J; Baruchel A; Creutzig U; Pieters R; Reinhardt D; Zwaan CM
    Haematologica; 2011 Mar; 96(3):384-92. PubMed ID: 21134981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of gene targets of mutant C/EBPα reveals a critical role for MSI2 in CEBPA-mutated AML.
    Heyes E; Schmidt L; Manhart G; Eder T; Proietti L; Grebien F
    Leukemia; 2021 Sep; 35(9):2526-2538. PubMed ID: 33623142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.
    Pabst T; Mueller BU; Zhang P; Radomska HS; Narravula S; Schnittger S; Behre G; Hiddemann W; Tenen DG
    Nat Genet; 2001 Mar; 27(3):263-70. PubMed ID: 11242107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C/EBPalphap30, a myeloid leukemia oncoprotein, limits G-CSF receptor expression but not terminal granulopoiesis via site-selective inhibition of C/EBP DNA binding.
    Cleaves R; Wang QF; Friedman AD
    Oncogene; 2004 Jan; 23(3):716-25. PubMed ID: 14737106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis.
    Quintana-Bustamante O; Lan-Lan Smith S; Griessinger E; Reyal Y; Vargaftig J; Lister TA; Fitzgibbon J; Bonnet D
    Leukemia; 2012 Jul; 26(7):1537-46. PubMed ID: 22371011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C/EBPα deregulation as a paradigm for leukemogenesis.
    Pulikkan JA; Tenen DG; Behre G
    Leukemia; 2017 Nov; 31(11):2279-2285. PubMed ID: 28720765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.